Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of “Buy” from Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned an average recommendation of “Buy” from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $47.46.

Several research firms have recently commented on DYN. BMO Capital Markets initiated coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. decreased their price target on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. Scotiabank assumed coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective on the stock. Chardan Capital restated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, March 17th. Finally, Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its position in shares of Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock worth $5,532,000 after acquiring an additional 698 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after purchasing an additional 721 shares in the last quarter. KBC Group NV boosted its stake in Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in Dyne Therapeutics by 5.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company’s stock valued at $237,000 after buying an additional 1,115 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its position in shares of Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company’s stock valued at $279,000 after buying an additional 1,249 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 20.4 %

Shares of DYN stock opened at $11.32 on Friday. The firm has a 50 day moving average of $10.38 and a 200-day moving average of $18.32. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -3.18 and a beta of 1.19. Dyne Therapeutics has a 52 week low of $6.36 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). Analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.